Wendy future of retail top

Mene Pangalo

Farxiga approved in treatment for heart failure with reduced ejection fraction

Farxiga approved in treatment for heart failure with reduced ejection fraction

NEW YORK — AstraZeneca’s Farxiga (dapagliflozin) has been approved in the US to reduce the risk of cardiovascular (CV) death and hospitalization for heart failure in adults with heart failure (NYHA class II-IV) with reduced ejection fraction (HFrEF) with and without type 2 diabetes (T2D). The approval by the Food and Drug Administration (FDA) was based

Centrum 7/6  banner